MediView, LLC is a medical device company based in Cleveland, Ohio, founded in 2017. The company specializes in developing augmented reality surgical navigation technology aimed at enhancing the accuracy and effectiveness of cancer therapies. Its flagship product, MediView, utilizes real-time, fused-holographic visualization to facilitate surgical navigation, allowing healthcare providers to examine patients through holograms rather than traditional 2D displays. This innovative approach not only improves the surgical process for oncologists but also supports telehealth applications, enabling remote collaboration during procedures. MediView's technology specifically targets the ablation and biopsy of cancerous tumors, positioning the company as a key player in the intersection of healthcare and advanced visualization technology.
Lucem Health develops a remote diagnostics platform designed to connect remote patient telemetry and biosensing devices with AI algorithms. Lucem's platform focuses on data ingest, orchestration, and connectivity, enabling clinicians to provide more effective continuous care and empower consumers to have better control of their health and well-being.
Ordr is a technology company that specializes in Internet of Things (IoT) security solutions designed for hyper-connected enterprises. Founded in 2015 and based in Santa Clara, California, Ordr develops an AI-based systems control engine that maps the device flow genome at scale. The company's platform employs machine learning to continuously inspect, classify, and establish baseline behaviors for each device within an organization. This unique software architecture enables real-time processing of large data volumes, allowing for closed-loop security. By generating tailored security policies for various device classes, Ordr integrates these measures with existing multi-vendor network and security infrastructures, helping organizations effectively manage and protect their business-critical devices and systems.
Karkinos Healthcare is technology-driven oncology focussed managed health care platform for the early detection and diagnosis of common cancers.
Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic and the University of Miami.
Theator is a technology company that focuses on enhancing surgical performance through its artificial intelligence-driven video platform, known as Minutes. Established in 2018, Theator operates from Tel Aviv, Israel, and has a presence in California. The platform utilizes a comprehensive dataset to provide surgeons with tools for content management and visual operative reporting, complete with analytics. By analyzing video data from surgical procedures, Minutes enables surgeons to evaluate their performance, review past cases, and prepare for future surgeries, thereby fostering continuous skill development. Theator aims to improve surgical outcomes and promote a more transparent operating room environment by partnering with surgeons and healthcare institutions to advance surgical intelligence and decision-support systems.
Collider activates, connects, and empowers early-stage entrepreneurs in Rochester, Minnesota.
Medically Home Group, Inc., based in Boston, Massachusetts, offers a virtual hospital program designed to deliver in-home medical care services. Founded in 2016, the company focuses on providing patient-centered care for individuals with serious or complex illnesses, including conditions such as heart failure, pneumonia, urinary tract infections, cellulitis, and respiratory issues. Medically Home's innovative model enables the safe transition of medical care from traditional hospital settings to patients' homes, allowing for centralized, on-demand management of acute medical needs. This approach connects patients with caregivers while facilitating monitoring and communication, ensuring that patients and their families receive comprehensive support in a familiar environment.
Tympany Medical focuses on advancing minimally invasive ear surgeries through innovative technology. The company has developed a specialized ear surgery device that provides a sterile endoscopic solution for complex procedures in otolaryngology. This device addresses key challenges related to the usability and flexibility of traditional endoscopes, allowing surgeons to benefit from enhanced visualization while preserving their two-handed operating techniques. By reducing the necessity for mastoidectomies, Tympany Medical aims to improve surgical outcomes and streamline the process of ear surgeries, ultimately enhancing patient care in the field of ENT.
SimBioSys, Inc. is developing a Computational Microscope that integrates state-of-the-art simulation techniques with a diverse set of experimental datasets to provide new insight into the behavior of cancers. The technology allows researchers to peer into the cancer microenvironment to identify the behavior of tumors: the cell phenotypes, how they interact with surrounding tissues, and how they prime their neighbors for invasion, all from the comfort of their computer desk.
TripleBlind, Inc. is a Kansas City-based company established in 2019 that provides a platform designed for secure collaboration involving sensitive data and algorithms. The company offers digital privacy as a service, equipping organizations with a suite of tools that allows them to share and utilize highly sensitive information in an encrypted environment. This innovative approach ensures that privacy is maintained, enabling entities to work together without the risk of compromising their data security.
Laplace Interventional
Series A in 2021
Laplace developing Transcatheter Tricuspid Valve Technology to offer an increase in life expectancy and an improvement to the quality of life to worldwide patients with tricuspid regurgitation.
JOGO is a Digital Therapeutics (DTx) uses the clinically proven science of neuroplasticity and biofeedback to treat patients with neuromuscular conditions and chronic pain. JOGO is composed of wearable sensors, and a patent protected Mobile App that leverages AI/ML and VR to provide treatment protocols and games that can be adapted for muscle relaxation, movement coordination, and neuro-muscular re-education. JOGO therapy is provided as JaaS (JOGO as a Service) at a doctor's office, home visit or via Telemedicine by certified JOGO therapists. JOGO received FDA 510K exemption in March 2020 during COVID-19 pandemic and JaaS is reimbursed by Medicare and commercial payers under neuro-muscular re-education.
Senda Biosciences is pioneering the field of Intersystems Biology to create novel treatments for human disease. Intersystems Biology focuses on how molecular connections between botanical, bacterial, and human cells—coevolved over millennia—define health and disease. Senda's Intersytems Biology discovery platform, built using new techniques in machine learning and computational biology, has been able to generate novel, actionable insights into the trillions of interspecies molecular connections in the human body, and harnesses the power of this "pharmacy within us" with novel pharmacological approaches. The power of the Senda platform is illustrated by six preclinical programs in oncology, neurology, chronic disease, and metabolic disease.
Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.
Medically Home Group, Inc., based in Boston, Massachusetts, offers a virtual hospital program designed to deliver in-home medical care services. Founded in 2016, the company focuses on providing patient-centered care for individuals with serious or complex illnesses, including conditions such as heart failure, pneumonia, urinary tract infections, cellulitis, and respiratory issues. Medically Home's innovative model enables the safe transition of medical care from traditional hospital settings to patients' homes, allowing for centralized, on-demand management of acute medical needs. This approach connects patients with caregivers while facilitating monitoring and communication, ensuring that patients and their families receive comprehensive support in a familiar environment.
Adaptive Phage Therapeutics, Inc. specializes in developing therapeutic solutions to combat the increasing threat of multi-drug resistant (MDR) bacteria. Founded in 2016 and based in Gaithersburg, Maryland, the company utilizes a unique resource known as PhageBank, which is an extensive and dynamic collection of bacteriophages—viruses that specifically target and attack harmful bacteria. Through a rapid system that matches these phages to individual patient bacterial infections, Adaptive Phage Therapeutics aims to enhance treatment options for patients suffering from MDR infections. Their innovative approach enables medical researchers to create tailored therapies that effectively detect and eliminate resistant bacterial strains.
Glooko is the universal diabetes platform that provides insights to improve outcomes for people with diabetes (PWDs) and their care teams. Glooko connects to the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient information such as glucose level, food, insulin, medications, blood pressure, diet and weight data. Trusted by the world’s leaders in diabetes care, we are in over 7,000 clinical locations and used by over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com.
Nuvolo Technologies Corporation offers a cloud-based enterprise asset management platform built on the ServiceNow framework. Established in 2013 and headquartered in Paramus, New Jersey, with additional offices in London, Bulgaria, and India, Nuvolo specializes in life-cycle management solutions for assets in clinics, laboratories, facilities, and manufacturing sectors. The company provides a comprehensive suite of services that includes implementation, support, tracking, reporting, and analytics, aimed at enhancing the user experience for mobile and remote workforces. Known for its commitment to innovation and customer service, Nuvolo has formed strategic partnerships with major firms such as Atos, KPMG, and Unisys to further its mission of becoming a leader in cloud-based enterprise asset management.
TripleBlind, Inc. is a Kansas City-based company established in 2019 that provides a platform designed for secure collaboration involving sensitive data and algorithms. The company offers digital privacy as a service, equipping organizations with a suite of tools that allows them to share and utilize highly sensitive information in an encrypted environment. This innovative approach ensures that privacy is maintained, enabling entities to work together without the risk of compromising their data security.
nference, Inc. operates an AI-based software platform that integrates and synthesizes biomedical knowledge from both unstructured and structured data sources, including scientific literature and real-world datasets. The platform utilizes advanced neural networks to automate the extraction of insights, facilitating real-time analysis for various applications within the life sciences sector, including drug discovery, development, and precision medicine. By addressing critical healthcare challenges, nference aims to enhance research and development efforts, as well as inform commercial strategies. Founded in 2013 and originally known as Lumen Biomics, nference is headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, India; Toronto, Canada; and Rochester, Minnesota.
Adaptive Phage Therapeutics, Inc. specializes in developing therapeutic solutions to combat the increasing threat of multi-drug resistant (MDR) bacteria. Founded in 2016 and based in Gaithersburg, Maryland, the company utilizes a unique resource known as PhageBank, which is an extensive and dynamic collection of bacteriophages—viruses that specifically target and attack harmful bacteria. Through a rapid system that matches these phages to individual patient bacterial infections, Adaptive Phage Therapeutics aims to enhance treatment options for patients suffering from MDR infections. Their innovative approach enables medical researchers to create tailored therapies that effectively detect and eliminate resistant bacterial strains.
Ordr is a technology company that specializes in Internet of Things (IoT) security solutions designed for hyper-connected enterprises. Founded in 2015 and based in Santa Clara, California, Ordr develops an AI-based systems control engine that maps the device flow genome at scale. The company's platform employs machine learning to continuously inspect, classify, and establish baseline behaviors for each device within an organization. This unique software architecture enables real-time processing of large data volumes, allowing for closed-loop security. By generating tailored security policies for various device classes, Ordr integrates these measures with existing multi-vendor network and security infrastructures, helping organizations effectively manage and protect their business-critical devices and systems.
Securisyn Medical, LLC is a medical technology company specializing in the manufacture and supply of oxygen delivery systems for patients on mechanical ventilation. Founded in 2011 and based in Highlands Ranch, Colorado, the company aims to enhance the safety of ventilated patients by preventing unplanned extubation and its related complications. Securisyn Medical's solutions are designed to provide reassurance to patients, their families, and healthcare practitioners while also reducing healthcare costs through ethical and sustainable practices. The company serves medical providers and facilities across the United States, focusing on collaborative efforts to eliminate preventable deaths associated with airway management in emergency and intensive care settings.
Progentec Diagnostics, Inc. develops a diagnostic test. It offers aiSLE DX, a platform that provides tests to help patients and their providers in managing the disease. The company’s tests include a flare prediction score, a reliable metric to proactively measure disease activity in SLE patients, and an early lupus diagnosis test. Progentec Diagnostics, Inc. was incorporated in 2015 and is headquartered in Oklahoma City, Oklahoma.
nference, Inc. operates an AI-based software platform that integrates and synthesizes biomedical knowledge from both unstructured and structured data sources, including scientific literature and real-world datasets. The platform utilizes advanced neural networks to automate the extraction of insights, facilitating real-time analysis for various applications within the life sciences sector, including drug discovery, development, and precision medicine. By addressing critical healthcare challenges, nference aims to enhance research and development efforts, as well as inform commercial strategies. Founded in 2013 and originally known as Lumen Biomics, nference is headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, India; Toronto, Canada; and Rochester, Minnesota.
Novome Biotechnologies, Inc. is a biotechnology company based in South San Francisco, California, that specializes in engineering bacteria from the human gut to address chronic diseases. Founded in 2015, the company has developed a platform for the controlled colonization of the gut with genetically engineered bacteria, known as Genetically Engineered Microbial Medicines (GEMMs). This innovative approach allows for sustained therapeutic interventions through the precise delivery of microbial activities. Novome's lead preclinical program targets hyperoxaluria by creating a therapeutic strain of bacteria aimed at degrading oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology platform to explore additional therapeutic applications.
Elysium Health offers health products built with science such as dietary supplements and anti-aging drugs. It seeks to solve challenges in health with science, to help people live healthier and longer lives. It works directly with the scientists, clinicians, and health professionals around the world to identify and develop the natural compounds. Its product is a proprietary formulation of two ingredients designed to support long-term well-being at the cellular level.
Hui-Gene Therapeutics Co., Ltd. engages in the research and development of single-gene disorders. It also develops pilot pipes in neurodegenerative diseases, vision disorders, and others. The company was founded in 2018 and is based in Shanghai, China.
NewCompliance Group B.V. develops and delivers dashboards that provide insights and improves the safety and efficiency in hospitals during the entire surgical process. It offers Operating Room Cockpit system that integrates and draws data from EMR, building, and other operating room (OR) equipment. The company’s OR Cockpit tracks, validates, and interprets data and display essential information needed by clinical staff during procedures. It also provides OR Financial that OR managers and hospital executives detailed and complete insight into the cost of individual surgeries by bringing together existing data; and OR Analytics platform that draws data from the EMR, facilities, and other major OR equipment to allow the user to design any type of combined and visual analysis in real-time. The company serves customers in Europe and the United States. The company was founded in 2006 and is based in The Hague, the Netherlands with additional offices in Nijmegen, the Netherlands; San Rafael, California; and Houston, Texas.
FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals.
AtriAN is commercializing technology created at Mayo Clinic in the US. AtriAN is an Irish Medical Device company based in Galway--A powerful and prolific hub for medical devices.AtriAN uses a gentle energy, micro Pulsed Electric Fields (mPEF) to only ablate hyperactivity. The other tissues such as the myocardium are spared.
Cadence Neuroscience is an early-stage company developing new medical device therapies for the treatment of epilepsy, central pain, and other neurological disorders. The company's core technology has been developed at Mayo Clinic and is under clinical evaluation. Its medical device therapies provide medical practitioners with the procedure that can be used to tailor brain stimulation therapy to each individual and enhance seizure control compared to currently used protocols.
Cadence Neuroscience was established in 2017 and is headquartered in Redmond, Washington.
Eko harnesses the power of smartphones and cloud data for monitoring patients with cardiovascular diseases. It has built a platform of non-invasive cardiovascular monitoring devices, clinical software, and point-of-care decision support algorithms to improve the delivery of cardiovascular care. In 2015, Eko launched the Eko Core Digital Stethoscope, the first FDA-cleared digital stethoscope on the market to wirelessly stream heart and lung sound to HIPAA-compliant software. For the first time in history, patient sounds can be integrated with electronic health records (EHRs) for more seamless referrals, documentation, and monitoring. Eko was established in 2013 and is based in Berkeley, California.
Qlaris Bio, Inc., a biotechnology company, develops therapies for debilitating ophthalmic diseases. It offers QLS-101, a therapy to reduce intraocular pressure. Qlaris Bio, Inc. was founded in 2017 and is headquartered in Wellesley, Massachusetts.
Safely Health operates an online platform designed to promote safe sexual practices by enabling users to import their test results and verify their STD and COVID-19 status. Founded in 2015 and based in Los Angeles, the company aims to create a trusted, private, and secure environment for individuals seeking to share their health information with potential partners. Safely Health is not just an app but a comprehensive healthcare initiative that collaborates with leading healthcare organizations, including Quest and Labcorp, as well as public health entities like the CDC. By partnering with nonprofit organizations, influencers, and social media platforms, Safely Health seeks to empower users to take control of their sexual health and reduce the spread of STDs, ultimately fostering a safer and more enjoyable dating experience.
GYANT.com, Inc. is a technology company based in Corte Madera, California, that specializes in developing an artificial intelligence-based chatbot application designed to enhance the connection between physicians and patients. The company's primary offering, the GYANT platform, assists healthcare providers by facilitating initial diagnostics, treatment recommendations, and prescription guidance through targeted patient inquiries. GYANT serves a variety of healthcare entities, including hospitals, health systems, and integrated delivery networks, aiming to streamline the patient experience. By implementing digital patient journeys, GYANT helps these organizations effectively capture new patients, improve service for existing ones, and automate various processes across their operations. Incorporated in 2016, GYANT focuses on creating solutions that navigate patients to appropriate care settings and in-network resources.
The pendulum is the microbial company to apply the discoveries of high-resolution, long-read DNA sequencing to the development of microbiome interventions targeting specific diseases. With a team of accomplished scientists, clinicians, engineers and innovators committed to Its mission of making millions healthier through microbiome-targeted medical probiotics.
GIBLIB is a California-based company and is the "Netflix" of Medical Education. It is a place for surgeons to share medical lectures and surgical videos. Founded in 2015, GIBLIB is headquartered in Los Angeles, California.
StemoniX Inc. is a biotechnology company that specializes in stem cell technologies to enhance drug discovery and personalized medicine. Founded in 2014 and headquartered in Minneapolis, Minnesota, with an additional office in La Jolla, California, StemoniX provides innovative platforms for pharmaceutical and research institutions. Its flagship solution focuses on the three-dimensional printing of stem-cell-derived human tissue, enabling the creation of living cells in larger formats. This technology is particularly beneficial for studying various diseases, including heart disease, dementia, breast cancer, autism, and ALS. By advancing the production and application of stem cell technologies, StemoniX aims to meet the evolving needs of the healthcare sector.
Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multiple neurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.
Marigold Health uses AI-augmented chat support groups to reach and retain patients with behavioral health needs in community-based treatment. Patients receive a personalized wraparound support while care teams see dramatic gains in capacity using patients to engage each other. We partner directly with treatment providers and managed care organizations in the Medicaid market.
Ambient Clinical Analytics is the creator of a software platform designed for data assimilation, communication and analytics. It is based on decision support tools initially deployed in the intensive care unit (ICU) or emergency department of hospitals. Our software consists of algorithms that mine data from electronic medical records (EMR). It then presents that data to the physicians and nurses so they may facilitate real-time clinical decision making and care delivery. These products are positioned as add on applications that are designed to easily integrate with the current major EMR providers.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.
The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine.
Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
Geneticure Inc. is a pharmacogenetic testing company focused on developing personalized medicine solutions for patients with hypertension. Founded in 2012 and based in Eden Prairie, Minnesota, the company offers a non-invasive genetic test that analyzes DNA from a cheek swab to identify genetic variants related to the renal, vascular, and cardiac systems. This information helps clinicians determine the most effective treatment options tailored to individual patients based on their unique genetic profiles. Geneticure's testing process includes DNA extraction, genotyping, and the provision of genetic results directly to healthcare providers, accompanied by a decision tree that prioritizes functional genes. This personalized approach aims to optimize blood pressure therapy and improve patient outcomes. Additionally, Geneticure is working on two more pharmacogenomic panels to expand its offerings in personalized medicine.
Helixis
Venture Round in 2018
Helixis, Inc. is a company that develops low-cost molecular diagnostic products.
Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.
Eko harnesses the power of smartphones and cloud data for monitoring patients with cardiovascular diseases. It has built a platform of non-invasive cardiovascular monitoring devices, clinical software, and point-of-care decision support algorithms to improve the delivery of cardiovascular care. In 2015, Eko launched the Eko Core Digital Stethoscope, the first FDA-cleared digital stethoscope on the market to wirelessly stream heart and lung sound to HIPAA-compliant software. For the first time in history, patient sounds can be integrated with electronic health records (EHRs) for more seamless referrals, documentation, and monitoring. Eko was established in 2013 and is based in Berkeley, California.
Progentec Diagnostics, Inc. develops a diagnostic test. It offers aiSLE DX, a platform that provides tests to help patients and their providers in managing the disease. The company’s tests include a flare prediction score, a reliable metric to proactively measure disease activity in SLE patients, and an early lupus diagnosis test. Progentec Diagnostics, Inc. was incorporated in 2015 and is headquartered in Oklahoma City, Oklahoma.
Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span. The company is focused on creating senolytic medicines that target and eliminate senescent cells, which are associated with various aging-related diseases. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal disorders and Phase Ib trials for knee osteoarthritis; UBX1325, in Phase I trials for diabetic macular edema; and UBX1967, targeting ophthalmologic diseases. Additionally, Unity is exploring therapeutic programs for pulmonary, neurological, kidney, and liver disorders. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. before rebranding in 2015.
Qrativ is a developer of a drug purposing platform designed to reinvent the way treatments for diseases with unmet medical need are discovered and developed. The company's platform ,Darwin.ai, identifies new uses for existing molecules for diseases with unmet medical need and uses machine learning and artificial intelligence for research and development, enabling patient to get treatments for diseases for which drugs are not available in the market.
Evelo Biosciences is a biotechnology company focused on developing oral biologics, specifically monoclonal microbials, for treating a range of inflammatory diseases and cancers. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company is advancing several candidates through various stages of clinical development. EDP1815, currently in a Phase 1b clinical study, aims to treat psoriasis and atopic dermatitis, while other candidates in pre-clinical stages target conditions such as psoriatic arthritis, asthma, and neuro-inflammatory diseases. Additionally, EDP1503 is undergoing Phase 1/2 trials for colorectal cancer and other malignancies. By utilizing naturally occurring monoclonal microbials, Evelo seeks to revolutionize drug discovery and development, offering a new approach to modulating systemic immunology and biology through oral delivery. This innovative platform has the potential to enhance the efficiency and effectiveness of treatments across various health conditions.
Glooko is the universal diabetes platform that provides insights to improve outcomes for people with diabetes (PWDs) and their care teams. Glooko connects to the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient information such as glucose level, food, insulin, medications, blood pressure, diet and weight data. Trusted by the world’s leaders in diabetes care, we are in over 7,000 clinical locations and used by over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com.
DayTwo Ltd. is a precision medicine company based in Tel Aviv-Yafo, Israel, founded in 2015. The company operates a web-based platform that leverages gut microbiome analysis to provide personalized health solutions, particularly for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease. DayTwo's innovative approach, grounded in research published in reputable scientific journals, recognizes that individuals react differently to foods, making tailored dietary recommendations essential for effective treatment. By analyzing stool samples, DayTwo creates individualized Food Prescriptions™ designed to optimize blood sugar levels, enhance energy, manage appetite, and support weight loss. Its services are delivered through a digital app, facilitated by Certified Diabetes Care and Education Specialists and Registered Dietitians, enabling users to monitor their progress and communicate with care providers. DayTwo tracks clinical outcomes such as A1C and Time In Range, offering a performance-based fee structure for users who adhere to its program.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies.
The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine.
Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
AliveCor has a device and application that will turn any smartphone into a clinical-quality electrocardiogram (ECG) recorder. AliveCor is pioneering the creation of FDA-cleared 'machine learning' techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. It specializes in the fields of healthcare, mobile device, and medicine.
It was founded in 2010 and headquartered in Mountain View, California.
Sensely is a developer of avatar and chatbot-based platform designed to assist insurance plan members and patients. The company's platform leverages conversational interfaces and provides virtual assistant solutions to insurance companies, pharmaceutical clients, and hospital systems worldwide, enabling enterprises to converse with their members in an entirely new way, combining the empathy of human conversation with the efficiency and scalability of the technology.
Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span. The company is focused on creating senolytic medicines that target and eliminate senescent cells, which are associated with various aging-related diseases. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal disorders and Phase Ib trials for knee osteoarthritis; UBX1325, in Phase I trials for diabetic macular edema; and UBX1967, targeting ophthalmologic diseases. Additionally, Unity is exploring therapeutic programs for pulmonary, neurological, kidney, and liver disorders. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. before rebranding in 2015.
Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.
Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases.
Cardero Therapeutics is a start-up pharmaceutical company that is developing a novel class of therapeutics that induces the formation of new mitochondria (mitochondrial biogenesis) and enhances mitochondrial function in response to metabolic demand. Chronic depletion of mitochondria, the principal source of cellular ATP, has been directly linked to the progression of heart failure, sarcopenia, and neurodegeneration. Cardero Therapeutics is collaborating with numerous academic medical centers to advance novel drug candidates structurally based on a newly discovered human hormone that appears to fundamentally regulate mitochondrial density and function in all tissues. Cardero Therapeutics believes that enhancing myocyte bioenergetics will comprise an innovative therapeutic approach complementary to currently available cardiovascular drugs. The company’s clinical development focus is the lethal cardiomyopathy associated with orphan diseases characterized by loss of mitochondria in muscle and heart, resulting in heart failure that is poorly responsive to current medical interventions. Initial clinical trials are directed toward Duchenne muscular dystrophy and Friedreich’s ataxia.
Helix is a prominent population genomics company that operates at the intersection of clinical care, research, and data analytics. The company provides an end-to-end platform designed to facilitate genomic research and the incorporation of genomic data into healthcare practices. Helix operates one of the largest CLIA/CAP-certified next-generation sequencing laboratories and utilizes its proprietary Exome+™ assay to support various aspects of population genomics. These include recruitment and engagement, clinically actionable disease screening, and the return of results. Additionally, Helix engages in large-scale genetic analysis and viral surveillance, delivering actionable genetic insights that aid health systems, life sciences companies, payers, and government entities in enhancing patient care and informing public health decisions.
Lifecode, Inc. operates as a next-generation-sequencing (NGS) based molecular diagnostics company. It develops a portfolio of NGS-based cancer assays, including the pan cancer somatic panel for use across metastatic cancer, rare and refractory cancers, standard of care exhausted, and patients looking for a clinical trial. The company also provides clinical information designed to help physicians make treatment decisions for their patients. Lifecode, Inc. was formerly known as Silicon Valley Biosystems, Inc. and changed its name to Lifecode, Inc. in January 2015. The company was incorporated in 2011 and is based in Foster City, California. As of February 24, 2016, Lifecode, Inc. operates as a subsidiary of MedGenome Labs Private Ltd.
Stride Health, Inc. operates a health benefits platform that allows independent workers and part-time employees to select and enroll in affordable health coverage. It offers dental plans, drive plans, and doctor and prescription insurance plans. The company serves customers in the United States. Stride Health, Inc. was formerly known as Covered, Inc. and changed its name to Stride Health, Inc. in March 2013. The company was incorporated in 2013 and is based in San Francisco, California.
Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span. The company is focused on creating senolytic medicines that target and eliminate senescent cells, which are associated with various aging-related diseases. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal disorders and Phase Ib trials for knee osteoarthritis; UBX1325, in Phase I trials for diabetic macular edema; and UBX1967, targeting ophthalmologic diseases. Additionally, Unity is exploring therapeutic programs for pulmonary, neurological, kidney, and liver disorders. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. before rebranding in 2015.
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.
Ambra Health is a medical data and image management software-as-a-service company that provides a cloud-based platform for healthcare providers. The platform is designed to enhance imaging innovation and improve collaborative care workflows by offering secure and easy access to medical images. It serves a diverse clientele, including major health systems and radiology practices, enabling them to streamline their operations and enhance patient care. Ambra Health's solutions focus on agility, interoperability, and user-friendly design, allowing organizations to adopt and integrate the technology effectively while improving business outcomes. The company aims to meet the evolving needs of the healthcare industry by delivering innovative medical image management solutions.
Chrono Therapeutics Inc., a digital transdermal drug delivery company, develops SmartStop, a digital nicotine replacement therapy. Its wearable solution tailors the timing and dose sizes of drugs, preempts predictable peak disease, and addiction symptoms with a device. The company was incorporated in 2003 and is based in Hayward, California.
Seres Health, now known as Seres Therapeutics, Inc., is a clinical-stage therapeutics company focused on the development of microbiome-based drugs aimed at treating various diseases associated with dysbiosis. The company specializes in Ecobiotic therapeutics designed to restore health by repairing the microbiome's function. Its lead product candidate, SER-109, is currently in Phase III clinical trials to prevent the recurrence of Clostridium difficile infection (CDI). Additionally, Seres is advancing several other candidates, including SER-287, which is in a Phase IIb study for ulcerative colitis, and SER-401, currently in Phase Ib trials for use in combination with checkpoint inhibitors in metastatic melanoma patients. Other candidates under development include SER-262 for initial CDI recurrence and SER-155 for modulating the microbiome in patients post-stem cell transplants. The company collaborates with organizations like Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and was founded in 2010 in Cambridge, Massachusetts.
Better provides symptom advice and the clinic's health database free of charge. The company helps collect all health records from various doctors and provide round-the-clock access to health-care workers who can help navigate insurance claims or advise on setting up appointments. The company was founded in 2013 and is based in Palo Alto, California.
The pendulum is the microbial company to apply the discoveries of high-resolution, long-read DNA sequencing to the development of microbiome interventions targeting specific diseases. With a team of accomplished scientists, clinicians, engineers and innovators committed to Its mission of making millions healthier through microbiome-targeted medical probiotics.
Ambient Clinical Analytics is the creator of a software platform designed for data assimilation, communication and analytics. It is based on decision support tools initially deployed in the intensive care unit (ICU) or emergency department of hospitals. Our software consists of algorithms that mine data from electronic medical records (EMR). It then presents that data to the physicians and nurses so they may facilitate real-time clinical decision making and care delivery. These products are positioned as add on applications that are designed to easily integrate with the current major EMR providers.
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Sanguine Biosciences, Inc. provides customizable specimen collection services across the United States, maintaining a biorepository of frozen samples from donors with various disease conditions. The company specializes in same-day collection and shipment of time-sensitive blood samples, ensuring that patient samples meet specific study requirements, including demographics and medical history. Sanguine supports clinical and pharmacogenomic studies by offering comprehensive biomaterials storage, sample collection with preferred anticoagulants, and the ability to aliquot samples into suitable volumes. The company collaborates with numerous U.S.-based clinics and hospitals for longitudinal studies and also offers products online. Founded in 2010 and located in Sherman Oaks, California, Sanguine utilizes innovative technology solutions to facilitate clinical trials, including participant recruitment and at-home data collection, thereby aiding clinicians in prescribing appropriate treatments.
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...
Anexon, Inc., a pharmaceutical company, develops therapeutics for cardiovascular diseases. The company is based in Cambridge, Massachusetts.
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Kardia Health Systems is a healthcare information technology firm offering the delivery of specialty medicine, starting with cardiology. Using Internet technology and a Software-as-a-Service (SaaS) business model, Kardia makes this technology accessible to practices of varying sizes. Kardia Health Systems, Inc. was incorporated in 2006 and is based in Golden Valley, Minnesota.
Kardia Health Systems is a healthcare information technology firm offering the delivery of specialty medicine, starting with cardiology. Using Internet technology and a Software-as-a-Service (SaaS) business model, Kardia makes this technology accessible to practices of varying sizes. Kardia Health Systems, Inc. was incorporated in 2006 and is based in Golden Valley, Minnesota.
Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.
Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
NBI Development is an implantable medical device company focused on the development of novel neuromodulation therapies. The company develops Neuromodulation, the use of electrical impulses to manage activity in the nervous system.
Naviscan, Inc. is the leader in organ-specific molecular imaging. The company designs, manufactures, and distributes a high-resolution PET scanner which provides unprecedented visualization of small body parts. While Naviscan’s PET scanner can image virtually any body part that can fit into the gantry, it is most often utilized as an adjunct to conventional imaging technologies by clinicians who stage and manage breast cancer. Surgeons, radiologists, nuclear physicians, and oncologists in hospitals and breast clinics use our compact, mobile and easy-to-use PET scanner to precisely characterize breast cancer, enhance surgical planning, monitor patient response to therapy, and evaluate suspected recurrence.
Torax Medical, Inc. develops and markets products/devices to restore the barrier function of sphincters. The company’s products include LINX, a reflux management system to treat patients diagnosed with gastroesophageal reflux disease; and FENIX, a continence restoration system for the treatment of fecal incontinence. It sells its products in Europe and the United States. Torax Medical, Inc. was founded in 2002 and is based in Shoreview, Minnesota. As of March 23, 2017, Torax Medical, Inc. operates as a subsidiary of Ethicon, Inc.